Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study

Hagop Kantarjian, Deborah Thomas, Jeffrey Jorgensen, Elias Jabbour, Partow Kebriaei, Michael Rytting, Sergernne York, Farhad Ravandi, Monica Kwari, Stefan Faderl, Mary Beth Rios, Jorge Cortes, Luis Fayad, Robert Tarnai, Sa A. Wang, Richard Champlin, Anjali Advani, Susan O'Brien

Research output: Contribution to journalArticle

Abstract

Background: The outlook for patients with refractory and relapsed acute lymphocytic leukaemia (ALL) is poor. CD22 is highly expressed in patients with ALL. Inotuzumab ozogamicin is a CD22 monoclonal antibody conjugated to the toxin calecheamicin. We did a phase 2 study to assess the efficacy of this antibody. Methods: We recruited patients at the MD Anderson Cancer Center, Houston, TX, USA, between June, 2010, and March, 2011. Adults and children with refractory and relapsed ALL were eligible. Ten adults were treated before enrolment of children started. Patients were given 1·8 mg/m 2 inotuzumab ozogamicin intravenously over 1 h every 3-4 weeks (the first three adults and three children received 1·3 mg/m 2 in the first course). The primary endpoint was overall response (complete response or marrow complete response with no recovery of platelet count or incomplete recovery of neutrophil and platelet counts). Analysis was done by intention to treat. This study is registered, number NCT01134575. Findings: 49 patients were enrolled and treated. Median age was 36 years (range 6-80). CD22 was expressed in more than 50% of blasts in all patients. The median number of courses was two (range one to five) and the median time between courses was 3 weeks (range 3-6). Nine (18%) patients had complete response, 19 (39%) had marrow complete response, 19 (39%) had resistant disease, and two (4%) died within 4 weeks of starting treatment. The overall response rate was 57% (95% CI 42-71). The most frequent adverse events during course one of treatment were fever (grade 1-2 in 20 patients, grade 3-4 in nine), hypotension (grade 1-2 in 12 patients, grade 3 in one), and liver-related toxic effects (bilirubin: grade 1-2 in 12 patients, grade 3 in two; raised aminotransferase concentration: grade 1-2 in 27 patients, grade 3 in one). Interpretation: Inotuzumab ozogamicin shows promise as a treatment for refractory and relapsed ALL. Funding: Pfizer.

Original languageEnglish (US)
Pages (from-to)403-411
Number of pages9
JournalThe Lancet Oncology
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Platelet Count
Inotuzumab Ozogamicin
Bone Marrow
Poisons
Transaminases
Bilirubin
Hypotension
Neutrophils
Fever
Therapeutics
Monoclonal Antibodies
Antibodies
Liver

ASJC Scopus subject areas

  • Oncology

Cite this

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia : A phase 2 study. / Kantarjian, Hagop; Thomas, Deborah; Jorgensen, Jeffrey; Jabbour, Elias; Kebriaei, Partow; Rytting, Michael; York, Sergernne; Ravandi, Farhad; Kwari, Monica; Faderl, Stefan; Rios, Mary Beth; Cortes, Jorge; Fayad, Luis; Tarnai, Robert; Wang, Sa A.; Champlin, Richard; Advani, Anjali; O'Brien, Susan.

In: The Lancet Oncology, Vol. 13, No. 4, 01.04.2012, p. 403-411.

Research output: Contribution to journalArticle

Kantarjian, H, Thomas, D, Jorgensen, J, Jabbour, E, Kebriaei, P, Rytting, M, York, S, Ravandi, F, Kwari, M, Faderl, S, Rios, MB, Cortes, J, Fayad, L, Tarnai, R, Wang, SA, Champlin, R, Advani, A & O'Brien, S 2012, 'Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study', The Lancet Oncology, vol. 13, no. 4, pp. 403-411. https://doi.org/10.1016/S1470-2045(11)70386-2
Kantarjian, Hagop ; Thomas, Deborah ; Jorgensen, Jeffrey ; Jabbour, Elias ; Kebriaei, Partow ; Rytting, Michael ; York, Sergernne ; Ravandi, Farhad ; Kwari, Monica ; Faderl, Stefan ; Rios, Mary Beth ; Cortes, Jorge ; Fayad, Luis ; Tarnai, Robert ; Wang, Sa A. ; Champlin, Richard ; Advani, Anjali ; O'Brien, Susan. / Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia : A phase 2 study. In: The Lancet Oncology. 2012 ; Vol. 13, No. 4. pp. 403-411.
@article{6fc300c4a19c410f867180b40fda6337,
title = "Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study",
abstract = "Background: The outlook for patients with refractory and relapsed acute lymphocytic leukaemia (ALL) is poor. CD22 is highly expressed in patients with ALL. Inotuzumab ozogamicin is a CD22 monoclonal antibody conjugated to the toxin calecheamicin. We did a phase 2 study to assess the efficacy of this antibody. Methods: We recruited patients at the MD Anderson Cancer Center, Houston, TX, USA, between June, 2010, and March, 2011. Adults and children with refractory and relapsed ALL were eligible. Ten adults were treated before enrolment of children started. Patients were given 1·8 mg/m 2 inotuzumab ozogamicin intravenously over 1 h every 3-4 weeks (the first three adults and three children received 1·3 mg/m 2 in the first course). The primary endpoint was overall response (complete response or marrow complete response with no recovery of platelet count or incomplete recovery of neutrophil and platelet counts). Analysis was done by intention to treat. This study is registered, number NCT01134575. Findings: 49 patients were enrolled and treated. Median age was 36 years (range 6-80). CD22 was expressed in more than 50{\%} of blasts in all patients. The median number of courses was two (range one to five) and the median time between courses was 3 weeks (range 3-6). Nine (18{\%}) patients had complete response, 19 (39{\%}) had marrow complete response, 19 (39{\%}) had resistant disease, and two (4{\%}) died within 4 weeks of starting treatment. The overall response rate was 57{\%} (95{\%} CI 42-71). The most frequent adverse events during course one of treatment were fever (grade 1-2 in 20 patients, grade 3-4 in nine), hypotension (grade 1-2 in 12 patients, grade 3 in one), and liver-related toxic effects (bilirubin: grade 1-2 in 12 patients, grade 3 in two; raised aminotransferase concentration: grade 1-2 in 27 patients, grade 3 in one). Interpretation: Inotuzumab ozogamicin shows promise as a treatment for refractory and relapsed ALL. Funding: Pfizer.",
author = "Hagop Kantarjian and Deborah Thomas and Jeffrey Jorgensen and Elias Jabbour and Partow Kebriaei and Michael Rytting and Sergernne York and Farhad Ravandi and Monica Kwari and Stefan Faderl and Rios, {Mary Beth} and Jorge Cortes and Luis Fayad and Robert Tarnai and Wang, {Sa A.} and Richard Champlin and Anjali Advani and Susan O'Brien",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/S1470-2045(11)70386-2",
language = "English (US)",
volume = "13",
pages = "403--411",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "4",

}

TY - JOUR

T1 - Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia

T2 - A phase 2 study

AU - Kantarjian, Hagop

AU - Thomas, Deborah

AU - Jorgensen, Jeffrey

AU - Jabbour, Elias

AU - Kebriaei, Partow

AU - Rytting, Michael

AU - York, Sergernne

AU - Ravandi, Farhad

AU - Kwari, Monica

AU - Faderl, Stefan

AU - Rios, Mary Beth

AU - Cortes, Jorge

AU - Fayad, Luis

AU - Tarnai, Robert

AU - Wang, Sa A.

AU - Champlin, Richard

AU - Advani, Anjali

AU - O'Brien, Susan

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: The outlook for patients with refractory and relapsed acute lymphocytic leukaemia (ALL) is poor. CD22 is highly expressed in patients with ALL. Inotuzumab ozogamicin is a CD22 monoclonal antibody conjugated to the toxin calecheamicin. We did a phase 2 study to assess the efficacy of this antibody. Methods: We recruited patients at the MD Anderson Cancer Center, Houston, TX, USA, between June, 2010, and March, 2011. Adults and children with refractory and relapsed ALL were eligible. Ten adults were treated before enrolment of children started. Patients were given 1·8 mg/m 2 inotuzumab ozogamicin intravenously over 1 h every 3-4 weeks (the first three adults and three children received 1·3 mg/m 2 in the first course). The primary endpoint was overall response (complete response or marrow complete response with no recovery of platelet count or incomplete recovery of neutrophil and platelet counts). Analysis was done by intention to treat. This study is registered, number NCT01134575. Findings: 49 patients were enrolled and treated. Median age was 36 years (range 6-80). CD22 was expressed in more than 50% of blasts in all patients. The median number of courses was two (range one to five) and the median time between courses was 3 weeks (range 3-6). Nine (18%) patients had complete response, 19 (39%) had marrow complete response, 19 (39%) had resistant disease, and two (4%) died within 4 weeks of starting treatment. The overall response rate was 57% (95% CI 42-71). The most frequent adverse events during course one of treatment were fever (grade 1-2 in 20 patients, grade 3-4 in nine), hypotension (grade 1-2 in 12 patients, grade 3 in one), and liver-related toxic effects (bilirubin: grade 1-2 in 12 patients, grade 3 in two; raised aminotransferase concentration: grade 1-2 in 27 patients, grade 3 in one). Interpretation: Inotuzumab ozogamicin shows promise as a treatment for refractory and relapsed ALL. Funding: Pfizer.

AB - Background: The outlook for patients with refractory and relapsed acute lymphocytic leukaemia (ALL) is poor. CD22 is highly expressed in patients with ALL. Inotuzumab ozogamicin is a CD22 monoclonal antibody conjugated to the toxin calecheamicin. We did a phase 2 study to assess the efficacy of this antibody. Methods: We recruited patients at the MD Anderson Cancer Center, Houston, TX, USA, between June, 2010, and March, 2011. Adults and children with refractory and relapsed ALL were eligible. Ten adults were treated before enrolment of children started. Patients were given 1·8 mg/m 2 inotuzumab ozogamicin intravenously over 1 h every 3-4 weeks (the first three adults and three children received 1·3 mg/m 2 in the first course). The primary endpoint was overall response (complete response or marrow complete response with no recovery of platelet count or incomplete recovery of neutrophil and platelet counts). Analysis was done by intention to treat. This study is registered, number NCT01134575. Findings: 49 patients were enrolled and treated. Median age was 36 years (range 6-80). CD22 was expressed in more than 50% of blasts in all patients. The median number of courses was two (range one to five) and the median time between courses was 3 weeks (range 3-6). Nine (18%) patients had complete response, 19 (39%) had marrow complete response, 19 (39%) had resistant disease, and two (4%) died within 4 weeks of starting treatment. The overall response rate was 57% (95% CI 42-71). The most frequent adverse events during course one of treatment were fever (grade 1-2 in 20 patients, grade 3-4 in nine), hypotension (grade 1-2 in 12 patients, grade 3 in one), and liver-related toxic effects (bilirubin: grade 1-2 in 12 patients, grade 3 in two; raised aminotransferase concentration: grade 1-2 in 27 patients, grade 3 in one). Interpretation: Inotuzumab ozogamicin shows promise as a treatment for refractory and relapsed ALL. Funding: Pfizer.

UR - http://www.scopus.com/inward/record.url?scp=84862786326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862786326&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(11)70386-2

DO - 10.1016/S1470-2045(11)70386-2

M3 - Article

C2 - 22357140

AN - SCOPUS:84862786326

VL - 13

SP - 403

EP - 411

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 4

ER -